Revenue Performance - Revenue for Q3 2024 was $4.2 million, a decrease of 23.6% compared to $5.5 million in Q3 2023, primarily due to timing of milestones and lower ion channel service revenue[3]. - Year-to-date revenue for the nine months ended September 30, 2024, was $15.6 million, down 46.8% from $29.3 million in the same period of 2023, largely due to lower milestone revenue[6]. - Total revenue for the three months ended September 30, 2024, was $4,172,000, a decrease from $5,477,000 in the same period of 2023, representing a decline of 23.8%[23]. - License and milestone revenue for Q3 2024 was $1,375,000, down from $2,010,000 in Q3 2023, a decrease of 31.6%[23]. - Service revenue increased to $2,479,000 in Q3 2024 from $3,016,000 in Q3 2023, a decrease of 17.8%[23]. Net Loss - Net loss for Q3 2024 was $16.4 million, or $0.16 per share, compared to a net loss of $15.7 million, or $0.16 per share, in Q3 2023[5]. - Year-to-date net loss for the nine months ended September 30, 2024, was $49.0 million, or $0.48 per share, compared to a net loss of $36.6 million, or $0.37 per share, for the same period in 2023[7]. - Net loss for Q3 2024 was $16,373,000, slightly higher than the net loss of $15,738,000 in Q3 2023[23]. - Net loss per share for Q3 2024 remained at $(0.16), consistent with Q3 2023[23]. Expenses - Research and development expenses for Q3 2024 were $13.3 million, a slight decrease from $13.9 million in Q3 2023, primarily due to lower share-based compensation[4]. - General and administrative expenses for Q3 2024 were $7.1 million, down from $8.5 million in Q3 2023, mainly due to lower legal and share-based compensation expenses[4]. - Operating expenses for Q3 2024 totaled $23,936,000, compared to $25,792,000 in Q3 2023, a reduction of 7.2%[23]. - Research and development expenses were $13,318,000 for Q3 2024, compared to $13,867,000 in Q3 2023, a decrease of 4.0%[23]. Cash and Investments - OmniAb had cash, cash equivalents, and short-term investments of $59.4 million as of September 30, 2024[7]. - Cash and cash equivalents increased to $27,236,000 as of September 30, 2024, from $16,358,000 at December 31, 2023[22]. - OmniAb expects total operating expenses in 2024 to be slightly less than in 2023 and anticipates ending 2024 with a cash balance between $50 million and $60 million[9]. Partnerships and Agreements - The company entered into three new platform license agreements during Q3 2024, increasing its active partners to 86 and active programs to 352[10]. - OmniAb sold 2.0 million shares of common stock through its ATM program in Q3 2024, generating net proceeds of $8.5 million[8]. Assets and Liabilities - Total assets decreased to $331,554,000 as of September 30, 2024, down from $375,225,000 at December 31, 2023, a decline of 11.6%[22]. - Total liabilities decreased to $39,826,000 as of September 30, 2024, from $60,640,000 at December 31, 2023, a reduction of 34.3%[22].

| --- | --- | --- | --- | --- | --- | |-----------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | Q2 2024 Financial Results & Business Update Nasdaq: OABI | | | | | | | August 8, 2024 | | | | | | 1 Disclaimer We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and ...

OmniAb, Inc. (NASDAQ:OABI) Q2 2024 Earnings Call August 8, 2024 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President and Chief Executive Officer Conference Call Participants Michael Sonntag - Leerink Partners Chad Wiatrowski - TD Cowen Stephen Willey - Stifel Conor McNamara - RBC Capital Markets Operator Good afternoon and welcome to OmniAb Incorporated 2024 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this conferenc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Per ...

Exhibit 99.1 OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. (August 8, 2024) – OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2024, and provided operating and partner program updates. "Second quarter results were in-line with our expectations and support our view of the full year. We advanced our business by adding new partnerships and ...

OmniAb, Inc. (NASDAQ:OABI) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President & Chief Executive Officer Conference Call Participants Nishant Gandhi - Truist Securities Jack Siedow - Craig-Hallum Michael Sonntag - Leerink Partners Jacqueline Kisa - Cowen Operator Good afternoon and welcome to OmniAb Inc. First Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a lis ...

| --- | --- | --- | --- | --- | |----------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | Q1 2024 Financial Results & Business Update | | | | | | Nasdaq: OABI | | | | | | May 9, 2024 | | | | | We caution you that this presentation contains forward-looking statements. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about the antibody industr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Pe ...

Exhibit 99.1 OmniAb Reports First Quarter 2024 Financial Results and Business Highlights Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. (May 9, 2024) – OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates. "The OmniAb team continued to make great progress this past quarter in advancing and expanding our portfolio and partnership base. We added three new platform licens ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________________ FORM 10-K _____________________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transitio ...